Propranolol

Propranolol is a beta-blocker. The US label read, for propranolol hydrochloride tablets (taken by mouth), lists several heart and vessel uses, of which this page records four: hypertension; decreasing angina frequency and increasing exercise tolerance in patients with angina pectoris; controlling the ventricular rate in atrial fibrillation with a rapid ventricular response; and reducing cardiovascular mortality in stable patients who have survived the acute phase of a myocardial infarction. The label also lists another heart use and uses outside the heart, which this page does not record.

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 8787; UNII F8A3652H1V. The label names the substance as propranolol hydrochloride, so UNII F8A3652H1V is the UNII of the hydrochloride salt and is a broad match. MeSH descriptor D011433 is Propranolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Amneal Pharmaceuticals NY LLC label for propranolol hydrochloride tablets, applications ANDA071972 and ANDA071976, effective 2026-06-10 in openFDA. The tablet label of a generic sponsor was read because it is a plain immediate-release tablet label; the Inderal LA, InnoPran XL and Hemangeol labels (other products of the same substance) were not read. This page records label indications and the class only: no trial result and no dose is given. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded.

Trials at a glance

The figures count the 1 registry trial in this atlas that names this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
1
Phase 3 or 4
0
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedAll statuses
Phase 2/311
All phases11

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII F8A3652H1V

Claims and evidence

Context People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction

Recipient
Recipient not specified
Population
Patients described in the heart and vessel passages of the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Propranolol hydrochloride tablets, in the Amneal Pharmaceuticals NY LLC version dated 2026-06-10 in openFDA, lists the medicine for the management of hypertension; to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response; and to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of myocardial infarction.

    Applies to Recipient not specified People for whom the US label of propranolol hydrochloride tablets lists one of the four heart or vessel indications recorded here: hypertension, angina pectoris, atrial fibrillation with a rapid ventricular response, survivors of the acute phase of myocardial infarction

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists migraine prophylaxis, essential tremor, hypertrophic subaortic stenosis and pheochromocytoma; those uses were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Propranolol hydrochloride tablets, Amneal Pharmaceuticals NY LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 14d0c95d-418f-40a8-bad3-e20c82424960 (manufacturer Amneal Pharmaceuticals NY LLC, application ANDA071972 and ANDA071976), returned on 2026-11-08. The label text is dated 2026-06-10 (effective_time). Other openFDA records of propranolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-06-10
      Source state
      Current
      Version fingerprint
      58aa79ab4fa6d5f88acbbfcb992c5236ebf3aee11476e255e1eefae3929e0d7d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Propranolol hydrochloride tablets, Amneal Pharmaceuticals NY LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 14d0c95d-418f-40a8-bad3-e20c82424960 (manufacturer Amneal Pharmaceuticals NY LLC, application ANDA071972 and ANDA071976), returned on 2026-11-08. The label text is dated 2026-06-10 (effective_time). Other openFDA records of propranolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260610.
      Retrieved
      Source effective date
      2026-06-10
      Source state
      Current
      Version fingerprint
      58aa79ab4fa6d5f88acbbfcb992c5236ebf3aee11476e255e1eefae3929e0d7d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

HEMANGEOL

No label from the application holder was found in the openFDA label dataset for application NDA205410. This page does not show another labeler's label in its place.

INDERAL

No label from the application holder was found in the openFDA label dataset for application NDA016418. This page does not show another labeler's label in its place.

INDERAL

No label from the application holder was found in the openFDA label dataset for application NDA019536. This page does not show another labeler's label in its place.

INDERAL LA

No label from the application holder was found in the openFDA label dataset for application NDA018553. This page does not show another labeler's label in its place.

INDERIDE LA 80/50

No label from the application holder was found in the openFDA label dataset for application NDA019059. This page does not show another labeler's label in its place.

INDERIDE-40/25

No label from the application holder was found in the openFDA label dataset for application NDA018031. This page does not show another labeler's label in its place.

INNOPRAN XL

No label from the application holder was found in the openFDA label dataset for application NDA021438. This page does not show another labeler's label in its place.

PROPRANOLOL HYDROCHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA016419. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA016418 INDERAL
  2. Approval NDA016419 PROPRANOLOL HYDROCHLORIDE
  3. Supplemental approval NDA016418 INDERAL
  4. Approval NDA018031 INDERIDE-40/25
  5. Supplemental approval NDA016418 INDERAL
  6. Approval NDA018553 INDERAL LA
  7. Supplemental approval NDA016418 INDERAL
  8. Supplemental approval NDA018553 INDERAL LA
  9. Approval NDA019059 INDERIDE LA 80/50
  10. Supplemental approval NDA018553 INDERAL LA
  11. Supplemental approval NDA016418 INDERAL
  12. Supplemental approval NDA016418 INDERAL
  13. Supplemental approval NDA016418 INDERAL
  14. Approval NDA019536 INDERAL
  15. Supplemental approval NDA018553 INDERAL LA
  16. Supplemental approval NDA018031 INDERIDE-40/25
  17. Approval NDA021438 INNOPRAN XL
  18. Approval NDA205410 HEMANGEOL

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 8

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 6 efficacy supplement approvals on record.

    ProductNDA016418

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA016419

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record. FDA lists it under 2 brand...

    ProductNDA018031

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA018553

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 3 brand...

    ProductNDA019059

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019536

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA021438

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA205410

Registry trials 1

Record details

Record id
cardio:propranolol
Content hash
977dc904e56a1c9095fd9e83a708cab1f569c8640f4f6d61167bc7bec2eb9d15